Fundraise

Arkana raises $3M pre-seed for python-inspired obesity drugs

What's the deal? Arkana TherapeuticsDealroom has a profile for this one. Try Dealroom →, a University of Colorado Boulder biotech, has closed an oversubscribed $3 million pre-seed round backed by the Boulder AngelsDealroom has a profile for this one. Try Dealroom → investor network. The startup is developing small-molecule therapies for obesity and metabolic disease.

What's the endgame? Arkana is working toward oral medicines that cut calorie intake and raise energy expenditure through mechanisms beyond GLP-1. The approach draws on python biology: after a large meal, Burmese pythons flood their blood with a metabolite that suppresses appetite.

The CU connection: The company is built on research from the lab of Leslie Leinwand, a distinguished professor at CU Boulder, where the team found a feeding-induced metabolite that rises 1,000-fold in pythons after they eat. Arkana was co-founded in 2025 by chief executive officer Jack Gugel, Leinwand, Thomas Martin, and Jonathan Long of Stanford Medicine.

Why now? Arkana was a member of the 2026 Ascent Deep Tech Accelerator and among the first recipients of Venture PartnersDealroom has a profile for this one. Try Dealroom →' therapeutics translational funding. It also won both the Lab Venture Challenge and the New Venture Challenge.

The bigger picture: The investment brings total capital deployed by Boulder Angels members to more than $750,000 since May 2025, with over $680,000 going to companies commercialising CU technology. The network plans to keep backing CU Boulder and Colorado ventures in 2027.

The signal: A $3 million pre-seed is a notable round at this stage, and the oversubscription points to investor appetite for obesity treatments that look past the dominant GLP-1 playbook.

Read more: colorado.edu

Image credit: "Burmese Python Closeup" by MyFWC Florida Fish and Wildlife, licensed under CC BY-ND 2.0

More top stories